Novartis strikes deal with Chinese firm to make Kymriah

Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

from Reuters: Health News https://ift.tt/2DC6QsC